- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Plus Therapeutics Inc (PSTV)
Plus Therapeutics Inc stock price live, this page displays NASDAQ PSTV stock exchange data. View the PSTV premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Plus Therapeutics Inc real time stock price chart below.
What Is the Plus Therapeutics Inc Stock Price Today?
The Plus Therapeutics Inc stock price today is 0.760.
What Is the Stock Symbol for Plus Therapeutics Inc?
The stock symbol for Plus Therapeutics Inc is ""PSTV.""
What Stock Exchange Does Plus Therapeutics Inc Trade On?
Plus Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Plus Therapeutics Inc a Good Stock to Buy?
Determining whether Plus Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PSTV quote. (ISIN: US72941H5090)
What Is the Plus Therapeutics Inc Stock Price Today?
The Plus Therapeutics Inc stock price today is 0.760.
What Is the Stock Symbol for Plus Therapeutics Inc?
The stock symbol for Plus Therapeutics Inc is ""PSTV.""
What Stock Exchange Does Plus Therapeutics Inc Trade On?
Plus Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Plus Therapeutics Inc a Good Stock to Buy?
Determining whether Plus Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the PSTV quote. (ISIN: US72941H5090)
NASDAQ
Currency in USD
0.760
+0.102(+15.50%)
Closed·
Pre Market
0.7600.000(0.00%)
·
Fair Value
An estimate of a Plus Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.689
0.804
52 wk Range
0.163
2.310
PSTV Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
PSTV is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a Plus Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
0.6890.804
52 wk Range
0.1632.310
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
PSTV Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Plus Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
9.167
Upside
+1,106.14%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Buy
Plus Therapeutics Inc Company Profile
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Plus Therapeutics Inc Earnings Call Summary for Q4/2024
- Net loss improved to $13 million in 2024 from $13.3 million in 2023, despite increased operating loss of $14.7 million
- FDA accepted and granted orphan designation for Ryobiq drug; multiple dose escalation trial planned for 2025
- Limited launch of C-Inside diagnostic test anticipated in 2025, with potential for 500,000 annual tests in U.S. market
- Grant revenue projected between $6-8 million for 2025; RESPECT GBM Phase II trial enrollment expected to complete by end of 2025
- Cash reserves decreased to $3.6 million from $8.6 million in 2023, highlighting critical cash flow management challenges
Last Updated: 27/03/2025, 23:10
Read Full TranscriptCompare PSTV to Peers and Sector
Metrics to compare | PSTV | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipPSTVPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.7x | −4.2x | −0.5x | |
PEG Ratio | 0.21 | −0.22 | 0.00 | |
Price/Book | −1.9x | 2.8x | 2.6x | |
Price / LTM Sales | 8.8x | 10.0x | 3.3x | |
Upside (Analyst Target) | - | 309.8% | 43.5% | |
Fair Value Upside | Unlock | 0.0% | 6.9% | Unlock |
Analyst Ratings
3 Buy
1 Hold
0 Sell
Ratings:
4 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 9.167
(+1,106.14% Upside)
Earnings
Latest Release
May 30, 2025
EPS / Forecast
-1.19 / -0.73
Revenue / Forecast
1.06M / --
People Also Watch
FAQ
What Stock Exchange Does Plus Therapeutics Trade On?
Plus Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Plus Therapeutics?
The stock symbol for Plus Therapeutics is "PSTV."
What Is the Plus Therapeutics Market Cap?
As of today, Plus Therapeutics market cap is 45.96M.
What Is Plus Therapeutics's Earnings Per Share (TTM)?
The Plus Therapeutics EPS (TTM) is -2.95.
From a Technical Analysis Perspective, Is PSTV a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Plus Therapeutics Stock Split?
Plus Therapeutics has split 5 times.
How Many Employees Does Plus Therapeutics Have?
Plus Therapeutics has 21 employees.
What is the current trading status of Plus Therapeutics (PSTV)?
As of 07 Aug 2025, Plus Therapeutics (PSTV) is trading at a price of 0.76, with a previous close of 0.76. The stock has fluctuated within a day range of 0.69 to 0.80, while its 52-week range spans from 0.16 to 2.31.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.